<DOC>
	<DOCNO>NCT01275183</DOCNO>
	<brief_summary>The propose study first-in-human pilot novel anti-cancer strategy : Metnase inhibition potentiate DNA damaging chemotherapy . The investigator conduct serial tumor biopsy subject HNSCC three timepoints : baseline , cisplatin , cisplatin-raltegravir . The investigator investigate immunohistochemical expression change Î³H2AX , Chk2 , Annexin V , three biomarkers DNA damage apoptosis . The study design identify intermediate signal potentiation cisplatin chemotherapy raltegravir HNSCC , justify future phase I/II study .</brief_summary>
	<brief_title>Pilot Study Raltegravir Cisplatin Squamous Cell Carcinoma Head Neck</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Histologic cytologic diagnosis squamous cell carcinoma head neck . All primary site eligible , include keratinize nasopharyngeal carcinoma ( WHO grade 1 2 ) carcinoma unknown primary . Either primary site metastatic locoregional tumor deposit ( eg . lymph node , parotid gland , subcutaneous nodule ) must amenable repeat , inoffice biopsy head neck surgeon . The patient must consider appropriate candidate cisplatin chemotherapy medical oncologist . Acceptable indication include induction chemotherapy prior surgery radiation localize disease , palliative chemotherapy advance disease . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Adequate bone marrow function , define absolute peripheral granulocyte count great 1,500 cells/mm3 platelet count great 100,000/mm3 absence regular red blood cell transfusion requirement . Adequate hepatic function total bilirubin le 2 mg/dl ; SGOT SGPT less 1.5 time upper limit normal ; alkaline phosphatase less 2.5 time upper limit normal . Creatinine clearance great equal 55 mL/min . Creatinine clearance estimate CockraftGault formula , use actual body weight . Women childbearing potential must negative pregnancy test . Men woman childbearing potential must willing consent use effective contraception treatment , least 3 month thereafter . Age great 18 . Able provide write , informed consent . No known brain metastasis . Pregnant woman nurse mother eligible trial . During first two weekly cycle cisplatin raltegravir , patient may receive concurrent antineoplastic therapy , include chemotherapy , biologic agent radiotherapy . For subsequent induction palliative chemotherapy cycle , patient may receive combination cisplatindocetaxelraltegravir , threeweek schedule specify protocol . No severe medical problem , include unstable angina ; myocardial infarction within past 6 month ; symptomatic congestive heart failure , NYHA grade II high ; active infection require antibiotic . History hypersensitivity reaction cisplatin . Patient know HIV disease . Any comorbid condition would preclude full compliance protocol . Patient le 3 year free another malignancy , except : ) malignancy nonmelanomatous skin cancer cervical carcinoma situ b ) primary malignancy consider clinically insignificant require active intervention . Peripheral neuropathy great equal grade 2 . Ongoing treatment rifampin , phenytoin , phenobarbital .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>HNSCC</keyword>
	<keyword>SCC</keyword>
	<keyword>head neck</keyword>
	<keyword>squamous cell</keyword>
	<keyword>nasopharyngeal</keyword>
</DOC>